STOCK TITAN
  1. Home
  2. Sec-filings
  3. LXEO
  4. [144] Lexeo Therapeutics, Inc. SEC Filing

Lexeo Therapeutics (LXEO) holder plans 1,304-share sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) has a stockholder, Jose Manuel Otero, filing a notice of proposed sale of company stock under Rule 144. The notice covers an intended sale of 1,304 shares of common stock through Fidelity Brokerage Services LLC on or after 08/18/2026.

The shares relate to restricted stock vesting on 08/17/2026 as part of compensation from the issuer. In the past three months, Otero has reported selling 1,302 shares on 05/18/2026 for $6,606.35 and 4,666 shares on 07/01/2026 for $20,919.08. A remark states that the sale includes shares needed to cover a tax obligation arising from settlement of a vested equity award.

Positive

  • None.

Negative

  • None.
Shares proposed to be sold 1,304 shares Intended Rule 144 sale of Lexeo Therapeutics common stock
Intended sale date 08/18/2026 Proposed date for Rule 144 sale through Fidelity
Recent sale 1 1,302 shares for $6,606.35 Common stock sold on 05/18/2026
Recent sale 2 4,666 shares for $20,919.08 Common stock sold on 07/01/2026
Vesting date 08/17/2026 Restricted stock vesting that underlies the planned sale
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
restricted stock vesting financial
"Common | 08/17/2026 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
vested equity award distribution financial
"resulting from the settlement of a vested equity award distribution."
attorney-in-fact regulatory
"as attorney-in-fact for Jose M. Otero"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing for LXEO by Jose Manuel Otero disclose?
The filing discloses that Jose Manuel Otero intends to sell 1,304 shares of Lexeo Therapeutics (LXEO) common stock under Rule 144. The sale will be executed through Fidelity Brokerage Services LLC and is linked to vested equity compensation.

How many Lexeo Therapeutics (LXEO) shares are proposed to be sold in this Form 144?
The notice states an intended sale of 1,304 shares of LXEO common stock. These shares are tied to restricted stock vesting dated 08/17/2026 and are to be sold through Fidelity Brokerage Services LLC on or after 08/18/2026.

What prior Lexeo Therapeutics (LXEO) stock sales by Jose Otero are disclosed?
The filing lists two prior sales: 1,302 shares sold on 05/18/2026 for $6,606.35, and 4,666 shares sold on 07/01/2026 for $20,919.08. These occurred within the three months preceding the new proposed sale.

Why does the Form 144 mention taxes for the LXEO share sale?
The remarks explain that the sale includes an amount of LXEO shares necessary to cover a tax obligation. This tax obligation arises from the settlement of a vested equity award distribution related to the filer’s compensation.

Who is executing the planned Lexeo Therapeutics (LXEO) share sale for Jose Otero?
The shares are to be sold through Fidelity Brokerage Services LLC, listed as the broker. The Form 144 is signed by Corey Walter as a duly authorized representative of Fidelity, acting as attorney-in-fact for Jose M. Otero.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR